PharmaShots | Incisive News in 3 Shots

Subscribe Now

Retinal Vascular Disorders

Samsung Bioepis and Biogen's Byooviz (biosimilar- ranibizumab) Receives the US FDA's Approval for the Treatment of Retinal Vascular Disorders

Samsung Bioepis and Biogen's Byooviz (biosimilar- ranibizumab) Receives the US FDA's Approval for the Treatment of Retinal Vascula...

September 21, 2021

Samsung Bioepis and Biogen Receive the CHMP's Positive Opinion Recommending Approval of Byooviz (biosimilar- ranibizumab) for Retinal Vascular Disorders

Samsung Bioepis and Biogen Receive the CHMP's Positive Opinion Recommending Approval of Byooviz (biosimilar- ranibizumab) for Reti...

June 28, 2021

Samsung Bioepis and Biogen Announces FDA Filing Acceptance of Lucentis' Biosimilar- SB11 for Retinal Vascular Disorders

Samsung Bioepis and Biogen Announces FDA Filing Acceptance of Lucentis' Biosimilar- SB11 for Retinal Vascular Disorders

November 18, 2020

Samsung Bioepis and Biogen Report the FDA's Acceptance of BLA for SB11 Proposed Biosimilar to Lucentis

Samsung Bioepis and Biogen Report the FDA's Acceptance of BLA for SB11 Proposed Biosimilar to Lucentis

November 18, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us